GU Cancer Clinical Trials

DISCLAIMER: All content found on cua.org is provided for information and education purposes. The medical information and clinical trials information is not intended to substitute for the advice of a physician, nor is it intended to provide legal advice. You should always consult your doctor for specific information on personal health matters, or other relevant professionals to ensure that your own circumstances are considered.

The CUA is not responsible in any manner for direct, indirect, special or consequential damages caused and/or arising from your use of cua.org.

Subspecialty
Prostate | AB | Recruiting
HREBA.CC-21-0073
18F-PSMA PET and MRI in the Primary Staging of Prostate Cancer Patients
Dr. Alexander Tamm & Dr. Adam Kinnaird
Start Date: February 10, 2022

NCT #: NCT05141760

SPONSOR: University of Alberta in collaboration with the Canadian Urological Association Scholarship Foundation.

INFO: https://clinicaltrials.gov/ct2/show/NCT05141760

CONTACT:  780-407-5800 ext 321

Renal | AB | Recruiting
SMART
Study of Minimally-invasive Ablative Renal Therapies (SMART) Registry (SMART)
Dr. Adam Kinnaird & Dr. Nicholas Dean
Start Date: January 27, 2022

NCT #: NCT05210933

SPONSOR: University of Alberta

INFO: https://clinicaltrials.gov/ct2/show/NCT05210933?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=3

CONTACT:

780-951-2326

780-690-6285

OTHER CANADIAN CENTRES: Calgary & Edmonton

Renal | AB, QC | Recruiting
SAMETA
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC (SAMETA)
AstraZeneca
Start Date: October 28, 2021

NCT #: NCT05043090

SPONSOR: AstraZeneca

INFO: https://clinicaltrials.gov/ct2/show/NCT05043090?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=9

CONTACT:  1-877-240-9479

OTHER CANADIAN CENTRES: Tom Baker Cancer Centre (Calgary), Jewish General Hospital (Montreal)

 

Bladder | AB, ON | Recruiting
MAIN-CAV
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
Dr. Shilpa Gupta
Start Date: October 26, 2021

NCT #: NCT05092958

SPONSOR: National Cancer Institute (NCI)

INFO: https://classic.clinicaltrials.gov/ct2/show/NCT05092958

CONTACT: 

Edmonton Contact: 780-432-8500                         

Toronto Contact: clinical.trials.@uhn.on.ca

OTHER CANADIAN CENTRES:

Cross Cancer Institute (Edmonton): Dr. M.P. Kolinsky                                    

University Health Network (Toronto): Dr. Srikala S. Sridhar

Renal | AB, BC, ON | Recruiting
AV-951-20-304
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
AVEO Pharmaceuticals
Start Date: September 9, 2021

NCT #: NCT04987203

SPONSOR: AVEO Pharmaceuticals in collaboration with Parexel and BMS

INFO: https://clinicaltrials.gov/ct2/show/NCT04987203?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=5

CONTACT: 857-400-0101

Bladder | AB, ON, QC | Recruiting
CA102-003
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Bristol-Myers Squibb
Start Date: August 29, 2021

NCT #: NCT04943900

SPONSOR: Bristol-Myers Squibb

INFO: https://clinicaltrials.gov/ct2/show/NCT04943900?recrs=abf&cond=Urothelial+Carcinoma&cntry=CA&draw=2&rank=14

CONTACT:  855-907-3286

OTHER CANADIAN CENTRES:

1. Mount Sinai Hospital (Toronto)
2. Centre recherche CHUM (Montreal)
3. Cross Cancer institute (Edmonton)

Prostate | ON | Recruiting
PRIAPUS
Potency preservation in prostate cancer patients treated with ultra sound-guided low-dose rate brachytherapy
Dr. Lucas Mendez
Start Date: June 27, 2021

NCT #: NCT04718987

SPONSOR: Lawson Health Research Institute 

INFO:  https://clinicaltrials.gov/ct2/show/NCT04718987

CONTACT:  519-685-8500 ext 54005

Renal | ON | Recruiting
ABILITY
A Beta-only IL-2 ImmunoTherapY (ABILITY) Study
Apollomics Inc.
Start Date: April 27, 2021

NCT #:  NCT05086692

SPONSOR: Medicenna Therapeutics

INFO:   https://clinicaltrials.gov/ct2/show/NCT05086692?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=26

CONTACT:  604-340-3081

OTHER CANADIAN CENTRES: Princess Margaret Cancer Centre (Toronto)         

 

Renal | AB, BC, ON, QC | Recruiting
MK-6482-012
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
Merck Sharp & Dohme LLC
Start Date: April 14, 2021

NCT #: NCT04736706

SPONSOR: Merck Sharp & Dohme LLC & Eisai

INFO: https://clinicaltrials.gov/ct2/show/NCT04736706?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=11

CONTACT:  1-888-577-8839

OTHER CANADIAN CENTRES: 

Tom Baker Cancer Centre (Calgary): Contact 403-521-3266.                
BC Cancer - Vancouver Center (Vancouver): Contact 604-877-6000         
Juravinski Cancer Centre (Hamilton): Contact 905-387-9495 x 63123            
Sunnybrook Research Institute (Toronto): Contact: 416-480-5847            
CHU de Quebec Universite Laval (Quebec City): 418-525-4444
 

Prostate | BC, ON | Recruiting
GUNS
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer (GUNS)
Dr. Martin E. Gleave
Start Date: March 21, 2021

NCT #: NCT04812366

SPONSOR: University of British Columbia in collaboration with Janssen Inc. UHN, Toronto.

INFO: https://classic.clinicaltrials.gov/ct2/show/NCT04812366

CONTACT: 

Jonathan Ma (BC): jma@prostatecentre.com                      
Anuja Parikh (UHN): Anuja.Parikh@uhn.ca 

OTHER CANADIAN CENTRES:

1. Vancouver Prostate Centre

2. University Health Network

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy